 Brian Greffe
Concepts (238)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma, Ewing | 3 | 2025 | 96 | 0.450 |
Why?
| | Kidney Neoplasms | 4 | 2021 | 401 | 0.390 |
Why?
| | Hepatoblastoma | 4 | 2022 | 46 | 0.390 |
Why?
| | Cisplatin | 3 | 2025 | 320 | 0.270 |
Why?
| | Liver Neoplasms | 4 | 2022 | 785 | 0.260 |
Why?
| | Bone Neoplasms | 2 | 2025 | 247 | 0.250 |
Why?
| | Testicular Neoplasms | 2 | 2017 | 110 | 0.230 |
Why?
| | Genetic Heterogeneity | 1 | 2025 | 59 | 0.230 |
Why?
| | Clonal Evolution | 1 | 2025 | 45 | 0.230 |
Why?
| | Rhabdomyosarcoma | 2 | 2019 | 72 | 0.230 |
Why?
| | Wilms Tumor | 2 | 2018 | 86 | 0.210 |
Why?
| | Granuloma, Plasma Cell | 1 | 2003 | 13 | 0.210 |
Why?
| | Dexamethasone | 1 | 2025 | 368 | 0.200 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 311 | 0.190 |
Why?
| | Antineoplastic Agents | 3 | 2025 | 2122 | 0.180 |
Why?
| | Neoplasms | 4 | 2025 | 2644 | 0.180 |
Why?
| | Hearing Loss | 1 | 2025 | 220 | 0.180 |
Why?
| | Pulmonary Blastoma | 1 | 2021 | 8 | 0.180 |
Why?
| | RNA, Neoplasm | 1 | 2021 | 82 | 0.180 |
Why?
| | Eye Neoplasms | 1 | 2021 | 18 | 0.180 |
Why?
| | Circulating Tumor DNA | 1 | 2021 | 34 | 0.170 |
Why?
| | Ribonuclease III | 1 | 2021 | 40 | 0.170 |
Why?
| | Biomarkers, Tumor | 2 | 2025 | 1272 | 0.170 |
Why?
| | Child | 25 | 2025 | 21822 | 0.170 |
Why?
| | DEAD-box RNA Helicases | 1 | 2021 | 76 | 0.170 |
Why?
| | Adolescent | 25 | 2025 | 21382 | 0.160 |
Why?
| | Protein C | 2 | 1989 | 59 | 0.160 |
Why?
| | Child, Preschool | 16 | 2025 | 11000 | 0.150 |
Why?
| | Hodgkin Disease | 2 | 2016 | 138 | 0.150 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2022 | 361 | 0.150 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 2 | 2016 | 77 | 0.140 |
Why?
| | Neoplasm Proteins | 1 | 2021 | 434 | 0.140 |
Why?
| | Cytodiagnosis | 1 | 2017 | 33 | 0.130 |
Why?
| | Frozen Sections | 1 | 2017 | 26 | 0.130 |
Why?
| | Survivors | 5 | 2016 | 487 | 0.130 |
Why?
| | Lung Diseases | 1 | 2003 | 768 | 0.130 |
Why?
| | Seminoma | 1 | 2017 | 20 | 0.130 |
Why?
| | Central Nervous System Neoplasms | 1 | 2019 | 156 | 0.130 |
Why?
| | Head and Neck Neoplasms | 2 | 2021 | 604 | 0.130 |
Why?
| | Nuclear Proteins | 1 | 2021 | 712 | 0.120 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2021 | 683 | 0.120 |
Why?
| | Health Planning | 1 | 2015 | 47 | 0.120 |
Why?
| | Male | 29 | 2025 | 67311 | 0.110 |
Why?
| | Osteosarcoma | 2 | 2007 | 74 | 0.110 |
Why?
| | Prognosis | 5 | 2025 | 4013 | 0.110 |
Why?
| | Abdomen, Acute | 1 | 1994 | 21 | 0.110 |
Why?
| | Liver Transplantation | 1 | 2022 | 871 | 0.110 |
Why?
| | Infant | 13 | 2025 | 9398 | 0.110 |
Why?
| | Transition to Adult Care | 1 | 2015 | 81 | 0.110 |
Why?
| | Ambulatory Care Facilities | 1 | 2015 | 231 | 0.100 |
Why?
| | Heart Diseases | 2 | 2016 | 346 | 0.100 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2013 | 19 | 0.100 |
Why?
| | Survival Rate | 5 | 2019 | 1963 | 0.100 |
Why?
| | Humans | 39 | 2025 | 136768 | 0.100 |
Why?
| | Sarcoma | 1 | 2015 | 188 | 0.100 |
Why?
| | Gene Rearrangement | 1 | 2013 | 149 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2013 | 139 | 0.090 |
Why?
| | Female | 27 | 2025 | 72796 | 0.090 |
Why?
| | Bone Marrow Transplantation | 3 | 2008 | 287 | 0.090 |
Why?
| | Denys-Drash Syndrome | 1 | 2011 | 4 | 0.090 |
Why?
| | Embolectomy | 1 | 2011 | 13 | 0.090 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2013 | 234 | 0.090 |
Why?
| | Tumor Lysis Syndrome | 1 | 2010 | 8 | 0.080 |
Why?
| | Lung Neoplasms | 3 | 2021 | 2489 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2010 | 1682 | 0.080 |
Why?
| | Mutation | 1 | 2021 | 3946 | 0.080 |
Why?
| | Lymphoma, B-Cell | 1 | 2010 | 106 | 0.080 |
Why?
| | Pulmonary Embolism | 1 | 2011 | 225 | 0.070 |
Why?
| | Risk Assessment | 3 | 2015 | 3432 | 0.070 |
Why?
| | Brain Neoplasms | 4 | 1999 | 1235 | 0.070 |
Why?
| | SEER Program | 3 | 2016 | 218 | 0.070 |
Why?
| | Retrospective Studies | 9 | 2022 | 15504 | 0.070 |
Why?
| | Leiomyosarcoma | 2 | 1998 | 28 | 0.070 |
Why?
| | Receptors, Erythropoietin | 1 | 2007 | 20 | 0.070 |
Why?
| | Young Adult | 6 | 2025 | 13129 | 0.070 |
Why?
| | Topotecan | 1 | 2007 | 13 | 0.070 |
Why?
| | Translocation, Genetic | 2 | 2021 | 105 | 0.070 |
Why?
| | Fetal Blood | 1 | 1989 | 327 | 0.070 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2007 | 68 | 0.070 |
Why?
| | Survival Analysis | 3 | 2018 | 1321 | 0.070 |
Why?
| | Paraneoplastic Syndromes, Nervous System | 1 | 2006 | 12 | 0.070 |
Why?
| | Carboplatin | 1 | 2006 | 142 | 0.060 |
Why?
| | Neuroblastoma | 2 | 2006 | 160 | 0.060 |
Why?
| | Leukemia | 1 | 2008 | 238 | 0.060 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2021 | 214 | 0.060 |
Why?
| | Injection, Intratympanic | 1 | 2025 | 2 | 0.060 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2006 | 92 | 0.060 |
Why?
| | Age Factors | 3 | 2018 | 3284 | 0.060 |
Why?
| | Pulmonary Artery | 1 | 2011 | 1086 | 0.060 |
Why?
| | Follow-Up Studies | 3 | 2025 | 5106 | 0.060 |
Why?
| | Adult | 14 | 2019 | 37630 | 0.060 |
Why?
| | Gels | 1 | 2025 | 80 | 0.060 |
Why?
| | Primary Health Care | 1 | 2015 | 1721 | 0.060 |
Why?
| | Killer Cells, Natural | 1 | 2008 | 443 | 0.060 |
Why?
| | Neoplasms, Second Primary | 1 | 2006 | 116 | 0.060 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2025 | 80 | 0.060 |
Why?
| | Immunologic Factors | 1 | 2006 | 236 | 0.050 |
Why?
| | Disease-Free Survival | 2 | 2019 | 685 | 0.050 |
Why?
| | Databases, Factual | 3 | 2018 | 1351 | 0.050 |
Why?
| | Abdominal Abscess | 1 | 2003 | 27 | 0.050 |
Why?
| | Incidence | 3 | 2007 | 2792 | 0.050 |
Why?
| | Stem Cells | 1 | 2008 | 592 | 0.050 |
Why?
| | Pulmonary Veno-Occlusive Disease | 1 | 2003 | 12 | 0.050 |
Why?
| | Spinal Neoplasms | 1 | 2003 | 32 | 0.050 |
Why?
| | Combined Modality Therapy | 3 | 2021 | 1231 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 452 | 0.050 |
Why?
| | Recurrence | 2 | 2003 | 1055 | 0.050 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 657 | 0.050 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 1 | 2021 | 25 | 0.040 |
Why?
| | RNA-Binding Protein EWS | 1 | 2021 | 26 | 0.040 |
Why?
| | Kidney Diseases, Cystic | 1 | 2021 | 24 | 0.040 |
Why?
| | Antibodies, Monoclonal | 2 | 2006 | 1430 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2025 | 951 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2025 | 672 | 0.040 |
Why?
| | Infant, Newborn | 4 | 2016 | 6033 | 0.040 |
Why?
| | Pneumothorax | 1 | 2021 | 38 | 0.040 |
Why?
| | Thyroid Diseases | 1 | 2000 | 36 | 0.040 |
Why?
| | Syndrome | 1 | 2021 | 357 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2021 | 172 | 0.040 |
Why?
| | Radiotherapy | 1 | 2021 | 201 | 0.040 |
Why?
| | Molecular Weight | 2 | 1989 | 335 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2025 | 1396 | 0.040 |
Why?
| | Smooth Muscle Tumor | 1 | 1998 | 6 | 0.040 |
Why?
| | Skull Neoplasms | 1 | 1998 | 23 | 0.040 |
Why?
| | Sarcoma, Synovial | 1 | 1998 | 21 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2021 | 403 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2021 | 1059 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2025 | 1772 | 0.040 |
Why?
| | Vincristine | 2 | 2010 | 116 | 0.040 |
Why?
| | Neoplasm Staging | 2 | 2017 | 1371 | 0.030 |
Why?
| | Fluorouracil | 2 | 2010 | 208 | 0.030 |
Why?
| | Leiomyoma | 1 | 1998 | 77 | 0.030 |
Why?
| | Common Variable Immunodeficiency | 1 | 1997 | 29 | 0.030 |
Why?
| | Intraoperative Period | 1 | 2017 | 59 | 0.030 |
Why?
| | Polymyositis | 1 | 1996 | 15 | 0.030 |
Why?
| | Epidemiological Monitoring | 1 | 2016 | 60 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 1058 | 0.030 |
Why?
| | Neutropenia | 1 | 1995 | 146 | 0.030 |
Why?
| | Organizational Innovation | 1 | 2015 | 138 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 2 | 2021 | 2667 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2015 | 191 | 0.030 |
Why?
| | Pneumatosis Cystoides Intestinalis | 1 | 1994 | 21 | 0.030 |
Why?
| | Graft vs Host Disease | 1 | 1996 | 248 | 0.030 |
Why?
| | Time Factors | 3 | 2018 | 6808 | 0.030 |
Why?
| | Fever | 1 | 1995 | 306 | 0.030 |
Why?
| | Klinefelter Syndrome | 1 | 1995 | 60 | 0.030 |
Why?
| | Laparotomy | 1 | 1994 | 109 | 0.030 |
Why?
| | Middle Aged | 7 | 2017 | 33228 | 0.030 |
Why?
| | Health Status | 1 | 1999 | 788 | 0.030 |
Why?
| | Flow Cytometry | 2 | 2008 | 1180 | 0.030 |
Why?
| | Emergencies | 1 | 1994 | 164 | 0.030 |
Why?
| | Aged | 4 | 2022 | 23794 | 0.030 |
Why?
| | Program Development | 1 | 2015 | 364 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3264 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2013 | 1733 | 0.020 |
Why?
| | Physical Examination | 1 | 1994 | 240 | 0.020 |
Why?
| | Transcription Factors | 1 | 2021 | 1718 | 0.020 |
Why?
| | Appendicitis | 1 | 1994 | 130 | 0.020 |
Why?
| | Immunocompromised Host | 1 | 1994 | 202 | 0.020 |
Why?
| | Chronic Disease | 2 | 2015 | 1785 | 0.020 |
Why?
| | Logistic Models | 1 | 2018 | 2067 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2015 | 1316 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2013 | 317 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2021 | 2412 | 0.020 |
Why?
| | Prevalence | 1 | 2019 | 2711 | 0.020 |
Why?
| | United States | 3 | 2017 | 14691 | 0.020 |
Why?
| | Radiography | 1 | 1994 | 822 | 0.020 |
Why?
| | Disease Management | 1 | 2015 | 624 | 0.020 |
Why?
| | Program Evaluation | 1 | 2015 | 889 | 0.020 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2010 | 35 | 0.020 |
Why?
| | Hyperuricemia | 1 | 2010 | 44 | 0.020 |
Why?
| | Hyperkalemia | 1 | 2010 | 24 | 0.020 |
Why?
| | Liver Function Tests | 1 | 2010 | 114 | 0.020 |
Why?
| | Necrosis | 1 | 2010 | 245 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1301 | 0.020 |
Why?
| | Maximum Tolerated Dose | 1 | 2007 | 199 | 0.020 |
Why?
| | Herpesvirus 4, Human | 2 | 1998 | 167 | 0.020 |
Why?
| | Respiratory Insufficiency | 1 | 2010 | 317 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2006 | 86 | 0.020 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2006 | 74 | 0.020 |
Why?
| | Urogenital Neoplasms | 1 | 2006 | 5 | 0.020 |
Why?
| | Behavior | 1 | 2006 | 90 | 0.020 |
Why?
| | Anti-Bacterial Agents | 2 | 1995 | 1798 | 0.020 |
Why?
| | Cerebrospinal Fluid | 1 | 2006 | 92 | 0.020 |
Why?
| | Thrombosis | 1 | 1989 | 366 | 0.020 |
Why?
| | Rituximab | 1 | 2006 | 176 | 0.010 |
Why?
| | Respiration, Artificial | 1 | 2010 | 642 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2006 | 387 | 0.010 |
Why?
| | Colorado | 1 | 2015 | 4518 | 0.010 |
Why?
| | Hemorrhage | 1 | 2010 | 721 | 0.010 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2006 | 77 | 0.010 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2010 | 614 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2016 | 7585 | 0.010 |
Why?
| | RNA, Viral | 2 | 1998 | 654 | 0.010 |
Why?
| | Survival | 1 | 2003 | 38 | 0.010 |
Why?
| | Stereotaxic Techniques | 1 | 2003 | 39 | 0.010 |
Why?
| | Thoracic Vertebrae | 1 | 2003 | 77 | 0.010 |
Why?
| | Transplantation, Autologous | 1 | 2003 | 238 | 0.010 |
Why?
| | Morbidity | 1 | 2003 | 323 | 0.010 |
Why?
| | Immunotherapy | 1 | 2006 | 640 | 0.010 |
Why?
| | Motor Activity | 1 | 2006 | 717 | 0.010 |
Why?
| | B-Lymphocytes | 1 | 2006 | 846 | 0.010 |
Why?
| | Hyperthyroidism | 1 | 2000 | 23 | 0.010 |
Why?
| | Sleep | 1 | 2006 | 753 | 0.010 |
Why?
| | Hypothyroidism | 1 | 2000 | 72 | 0.010 |
Why?
| | Thyroid Nodule | 1 | 2000 | 56 | 0.010 |
Why?
| | Sella Turcica | 1 | 1998 | 18 | 0.010 |
Why?
| | Tumor Virus Infections | 1 | 1998 | 46 | 0.010 |
Why?
| | Health Status Indicators | 1 | 1999 | 168 | 0.010 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 1998 | 69 | 0.010 |
Why?
| | Fatal Outcome | 1 | 1998 | 303 | 0.010 |
Why?
| | Herpesviridae Infections | 1 | 1998 | 149 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 1997 | 432 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 1997 | 316 | 0.010 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1998 | 230 | 0.010 |
Why?
| | Thyroid Neoplasms | 1 | 2000 | 337 | 0.010 |
Why?
| | Prednisone | 1 | 1996 | 239 | 0.010 |
Why?
| | Pineal Gland | 1 | 1995 | 16 | 0.010 |
Why?
| | Leukocyte Count | 1 | 1995 | 329 | 0.010 |
Why?
| | Anesthesia, Dental | 1 | 1974 | 22 | 0.010 |
Why?
| | Tooth Extraction | 1 | 1974 | 25 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 2 | 1998 | 3555 | 0.010 |
Why?
| | Anesthesia, General | 1 | 1974 | 71 | 0.010 |
Why?
| | Anti-Inflammatory Agents | 1 | 1996 | 496 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 1996 | 1481 | 0.010 |
Why?
| | Quality of Life | 1 | 2003 | 2878 | 0.010 |
Why?
| | Cohort Studies | 1 | 2000 | 5701 | 0.010 |
Why?
| | Neutrophils | 1 | 1995 | 1236 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2003 | 10744 | 0.000 |
Why?
| | Surveys and Questionnaires | 1 | 1999 | 5742 | 0.000 |
Why?
| | Prospective Studies | 1 | 1995 | 7572 | 0.000 |
Why?
| | Risk Factors | 1 | 1995 | 10326 | 0.000 |
Why?
| | Oral Hemorrhage | 1 | 1974 | 3 | 0.000 |
Why?
| | Tachycardia | 1 | 1974 | 57 | 0.000 |
Why?
| | Angina Pectoris | 1 | 1974 | 65 | 0.000 |
Why?
| | Postoperative Care | 1 | 1974 | 261 | 0.000 |
Why?
| | Arrhythmias, Cardiac | 1 | 1974 | 333 | 0.000 |
Why?
| | Anticoagulants | 1 | 1974 | 663 | 0.000 |
Why?
|
|
Greffe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|